Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.61 |
| ▸ | LIPE | Q05469 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 4/20 | 0.50 |
| ▸ | MMP13 | P45452 | 4/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.46 |
| ▸ | LIPC | P11150 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | LPL | P06858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10607315 | 0.92 | EPHX2 (0.56) | EPHX2LIPEADRB2TEAD1MMP2 | |
| SCHEMBL23365220 | 0.87 | EPHX2 (0.62) | EPHX2LIPEADRB2TEAD1MMP2 | |
| SCHEMBL2092945 | 0.86 | LIPE (0.61) | EPHX2LIPEADRB2TEAD1MMP2 | |
| SCHEMBL3222147 | 0.86 | EPHX2 (0.58) | EPHX2LIPEADRB2TEAD1MMP2 | |
| SCHEMBL2092942 | 0.86 | EPHX2 (0.58) | EPHX2LIPEADRB2TEAD1MMP2 | |
| SCHEMBL10606827 | 0.84 | EPHX2 (0.64) | EPHX2LIPECNR1 | |
| SCHEMBL14413624 | 0.82 | EPHX2 (0.64) | EPHX2LIPEADRB2TEAD1MMP2 | |
| SCHEMBL11001792 | 0.82 | LIPE (0.67) | EPHX2LIPEADRB2TEAD1MMP2 | |
| SCHEMBL23632233 | 0.82 | EPHX2 (0.57) | EPHX2LIPEADRB2TEAD1MMP2 | |
| SCHEMBL23632235 | 0.82 | EPHX2 (0.57) | EPHX2LIPEADRB2TEAD1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0147909-B1 | ARYLOXY-N-(AMINOALKYL)-1-PYRROLIDINE AND PIPERIDINE CARBOXAMIDES AND CARBOTHIOAMIDES HAVING ANTIARRHYTHMIC ACTIVITY | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4547514-A | Aryloxy-N-(aminoalkyl)-1-pyrrolidine and piperidine carboxamides and carbothioamides having antiarrhythmic activity | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-10-15 | — | — | US | disclosed |
| EP-0147909-A1 | Aryloxy-N-(aminoalkyl)-1-pyrrolidine and piperidine carboxamides and carbothioamides having antiarrhythmic activity | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | EPHX2 3662/4885LIPE 4705/4885ADRB2 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.